Clinical Trials
27 trialsAdministering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
National Institutes of Health Clinical Center (CC)
Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)
National Cancer Institute (NCI)
Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
National Institutes of Health Clinical Center (CC)
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
National Cancer Institute (NCI)
Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer
National Cancer Institute (NCI)
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
National Cancer Institute (NCI)
VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
National Cancer Institute (NCI)
A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum
National Institutes of Health Clinical Center (CC)
Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
National Cancer Institute (NCI)
AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer
National Cancer Institute (NCI)
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
National Cancer Institute (NCI)
Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer
National Cancer Institute (NCI)
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
National Institutes of Health Clinical Center (CC)
Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer
National Cancer Institute (NCI)
Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia
National Cancer Institute (NCI)
Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia
National Cancer Institute (NCI)
Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
National Institutes of Health Clinical Center (CC)
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
National Cancer Institute (NCI)
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma
National Cancer Institute (NCI)
Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
National Cancer Institute (NCI)
Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery
National Cancer Institute (NCI)
RO4929097 in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer
National Cancer Institute (NCI)